Under the Papersionk Reduction Act of 1995, no persons are required to re-

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		10507052			
Filing Date		2004-09-09			
First Named Inventor AGA		THA COLANGELO			
Art Unit		2673			
Examiner Name					
Attorney Docket Number	er	CA920010094US1			

				Attorney Docket Numb		ket Number	CA920010094US1				_
							-				
					U.S.	PATENTS			Remove		_
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue [	Issue Date Name of Patentee or Applicant		Relev	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1										
If you wisl	h to a	i dd additional U.S. Pater	nt citatio	n inform	ation pl	lease click the	Add button.		Add		_
			U.S.P	ATENT	APPLI	CATION PUBL	LICATIONS		Remove		_
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	ation	Name of Patentee or Applicant of cited Document		Relev	s,Columns,Li ant Passage es Appear		
	1										
If you wis	h to a	ı dd additional U.S. Publi	shed Ap	plication	citatio	n information p	lease click the Ad	d butto	n. Add		_
				FOREIG	GN PAT	TENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code <sup>4</sup>	Publication Date	Name of Patente Applicant of cite Document	d d	Pages,Colur where Relev Passages or Figures App	ant Relevant	+=
	1	PUPA 200038284	KR			2000-07-05	YOON, TAI CHEC	OL.			Г
	2	PUPA 200174623	KR			2001-08-04	KIM,HYEON GI				С
If you wis	h to a	dd additional Foreign P	atent Do	cument	citation	information pl	ease click the Ad	d button	Add		_

	Application Number		10507052	
INFORMATION DIGGI COURT	Filing Date		2004-09-09	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	AGA	THA COLANGELO	
(Not for submission under 37 CFR 1.99)	Art Unit		2673	
(·	Examiner Name			
	Attorney Docket Numb	er	CA920010094US1	

Examine Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where publisher.	Ţ5
	1		

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

# Examiner Signature Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Knd Codes of USPTO Patent Documents at year LISPTO, GDU or MPEP 901.04. <sup>2</sup> Either office that issued the document, by the bo-later code (WIPO Standard ST3.) <sup>3</sup> Sor Juapanes patent concuments, by managed the common state of the Empower managed code the search counterful. <sup>4</sup> Knill of document by the appropriate symbols as adicated on the document under WIPO Standard ST.16 if possible. <sup>3</sup> Applicant is to place a check mark here if English Imaguage translation is attached.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10507052
Filing Date		2004-09-09
First Named Inventor AGA		THA COLANGELO
Art Unit		2673
Examiner Name		
Attorney Docket Numb	er	CA920010094US1

#### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication of from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information siclosure statement. Sec 37 CFR 197(a)(1).

## OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 175(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 179(c) and the statement. See 37 CFR 179(c) and the statement. See 37 CFR 179(c) and the statement is set to the statement of the statement of

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

of the agreeter.								
Signature	/Mark S. Walker/	Date (YYYY-MM-DD)	2006-07-12					
Name/Print	Mark S. Walker	Registration Number	30699					

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, U.S. operationed for Commence, P. 0. Bot 1450, Alexandria, V.S. 2213.1-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.2313.1-1450.

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.